Vemurafenib and cutaneous adverse events - report of five cases

Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Giselle de Barros, Mendes, Adriana Pessoa, de Macedo, Mariana Petaccia, Pinto, Clóvis Antônio Lopes, Gibbons, Ivana Lameiras, Duprat Neto, João Pedreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540563/
https://www.ncbi.nlm.nih.gov/pubmed/26312729
http://dx.doi.org/10.1590/abd1806-4841.20153841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540563/
https://www.ncbi.nlm.nih.gov/pubmed/26312729
http://dx.doi.org/10.1590/abd1806-4841.20153841

Ejemplares similares